| __timestamp | ADMA Biologics, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3742367 | 14400000 |
| Thursday, January 1, 2015 | 4311461 | 33800000 |
| Friday, January 1, 2016 | 6360761 | 35900000 |
| Sunday, January 1, 2017 | 29164321 | 1254000 |
| Monday, January 1, 2018 | 42194635 | 4889000 |
| Tuesday, January 1, 2019 | 39504238 | 7400000 |
| Wednesday, January 1, 2020 | 61291426 | 10100000 |
| Friday, January 1, 2021 | 79769341 | 14300000 |
| Saturday, January 1, 2022 | 118814535 | 23200000 |
| Sunday, January 1, 2023 | 169273000 | 39700000 |
| Monday, January 1, 2024 | 34000000 |
Igniting the spark of knowledge
In the ever-evolving biotech industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Neurocrine Biosciences, Inc. and ADMA Biologics, Inc. over the past decade. From 2014 to 2023, ADMA Biologics experienced a staggering 4,400% increase in its cost of revenue, peaking at $169 million in 2023. This growth reflects ADMA's aggressive expansion and scaling efforts. In contrast, Neurocrine Biosciences showed a more modest increase of 175% over the same period, reaching $39.7 million in 2023. This steady rise suggests a more controlled growth strategy, focusing on sustainable development. The data highlights the contrasting approaches of these two companies in managing their operational costs, offering valuable insights for potential investors. As the biotech sector continues to grow, understanding these financial dynamics becomes increasingly important.
Cost of Revenue Comparison: Eli Lilly and Company vs Neurocrine Biosciences, Inc.
Cost of Revenue Comparison: AbbVie Inc. vs Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Vertex Pharmaceuticals Incorporated and Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Vertex Pharmaceuticals Incorporated and ADMA Biologics, Inc.
Neurocrine Biosciences, Inc. vs Bio-Techne Corporation: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Telix Pharmaceuticals Limited
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Bausch Health Companies Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Mesoblast Limited
Cost Insights: Breaking Down Bio-Techne Corporation and ADMA Biologics, Inc.'s Expenses
Catalent, Inc. vs ADMA Biologics, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: ADMA Biologics, Inc. vs Geron Corporation
Cost of Revenue Comparison: ADMA Biologics, Inc. vs Mesoblast Limited